Pasithea Therapeutics (KTTA) Accumulated Depreciation (2022 - 2025)

Pasithea Therapeutics has reported Accumulated Depreciation for 4 years, with the latest figure at $47939.0 in Q2 2025.

• Quarterly Accumulated Depreciation rose 45.62% year-over-year to $47939.0 in Q2 2025, while the trailing twelve-month figure through Jun 2025 was $47939.0 (up 45.62% YoY) and the FY2024 annual result came in at $42353.0, up 80.32% from the prior year.
• Accumulated Depreciation improved to $47939.0 in Q2 2025 per KTTA's latest filing, from $43981.0 in the prior quarter.
• Over five years, Accumulated Depreciation peaked at $47939.0 in Q2 2025 and troughed at $3559.0 in Q4 2022.
• A 4-year average of $32510.1 and a median of $35278.0 in 2024 frame the typical range for Accumulated Depreciation.
• The sharpest annual moves came in 2023 and 2025: Accumulated Depreciation surged 559.96% in 2023, then soared 45.62% in 2025.
• Over 4 years, Accumulated Depreciation stood at $3559.0 in 2022, then soared by 559.96% to $23488.0 in 2023, then jumped by 80.32% to $42353.0 in 2024, then grew by 13.19% to $47939.0 in 2025.
• According to Business Quant data, Accumulated Depreciation over the past three periods registered $47939.0, $43981.0, and $42353.0 for Q2 2025, Q1 2025, and Q4 2024 respectively.